A carregar...
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease
BACKGROUND: In TEMPO 3:4, the vasopressin V2-receptor antagonist tolvaptan slowed kidney growth and resulted in function decline in autosomal dominant polycystic kidney disease (ADPKD) patients with relatively preserved kidney function. METHODS: Prospective, phase 3b, multi-center, randomized-withdr...
Na minha lista:
| Publicado no: | Am J Nephrol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5497717/ https://ncbi.nlm.nih.gov/pubmed/28166521 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000456087 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|